Safety and efficacy of combined therapy with pegylated interferon alpha-2b and ribavirin for Egyptian children with HCV infection / (Record no. 54316)

MARC details
000 -LEADER
fixed length control field 03318cam a2200349 a 4500
003 - CONTROL NUMBER IDENTIFIER
control field EG-GiCUC
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250223031404.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 160106s2015 ua dh f m 000 0 eng d
040 ## - CATALOGING SOURCE
Original cataloging agency EG-GiCUC
Language of cataloging eng
Transcribing agency EG-GiCUC
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title eng
049 ## - LOCAL HOLDINGS (OCLC)
Holding library Deposite
097 ## - Thesis Degree
Thesis Level M.Sc
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
Classification number Cai01.11.28.M.Sc.2015.Sa.S
100 0# - MAIN ENTRY--PERSONAL NAME
Personal name Samah Abdelhameed Mubarak
245 10 - TITLE STATEMENT
Title Safety and efficacy of combined therapy with pegylated interferon alpha-2b and ribavirin for Egyptian children with HCV infection /
Statement of responsibility, etc. Samah Abdel Hameed Mubarak ; Supervised Hanaa Mostafa El-Karaksy , Doa`A Ahmed Essawi Saleh , Engy Adel Mohammad Mogahed
246 15 - VARYING FORM OF TITLE
Title proper/short title سلامة و فاعلية العلاج بالانترفيرون الفا -2بي مع وريبافيرين للاطفال المصابين بالالتهاب الكبدى فيروس س
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Cairo :
Name of publisher, distributor, etc. Samah Abdelhameed Mubarak ,
Date of publication, distribution, etc. 2015
300 ## - PHYSICAL DESCRIPTION
Extent 119 P. :
Other physical details charts , facsimiles ;
Dimensions 25cm
502 ## - DISSERTATION NOTE
Dissertation note Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
520 ## - SUMMARY, ETC.
Summary, etc. The study was performed on 66 pediatric patients (3-18 years of age), of both sexes, infected with HCV GT4. Children were treated with PEG IFN Ü 2b in a dose of 60 æg/m2, given as subcutaneous injection once weekly and RBV in a dose of 15 mg/kg in 2 divided doses orally, daily. Treatment outcome was assessed by the absence of detectable viral RNA in blood 24 weeks after end of treatment, i.e., sustained virological response (SVR). Safety was assessed by performing specific investigations, weight and height measurements and questionnaires directed to the patients at specific intervals. Results: Forty three out of the 66 included patients (65.2%) were males. Mean age of the patients at the time of enrollment in the study was 10.9 + 3.5 years. SVR was achieved in 28 patients (42.4%). Comparing the group of responders to the non responders, history of treated malignancies was significantly commoner in non responders group (P= 0.03), responders had significantly higher levels of absolute neutrophilic count and lower levels of GGT (P= 0.009 and 0.003 respectively). HCV PCR level was significantly lower in responders (P=0.03). Fever was the most frequently reported side effect occurring in 98.5% of the patients followed by musculoskeletal symptoms. Neutropenia was observed in 36 patients (54.6%) which necessitated treatment discontinuation in only one patient. Seventy percent of children, who received the combined therapy for a total of 48 weeks, showed a drop in both weight and height percentiles at the end of the 48 weeks. Conclusion: The currently available treatment, PEG-IFNÜ 2b and RBV, for HCV GT 4 in pediatric patients has modest SVR of 42.4% with numerous adverse events necessitating meticulous monitoring to optimize care of the patients. Side effects could be managed with dose modifications and specific treatment when necessary
530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE
Additional physical form available note Issued also as CD
653 #4 - INDEX TERM--UNCONTROLLED
Uncontrolled term HCV
653 #4 - INDEX TERM--UNCONTROLLED
Uncontrolled term INF
653 #4 - INDEX TERM--UNCONTROLLED
Uncontrolled term RBV
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Doa`A Ahmed Essawi Saleh ,
Relator term
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Engy Adel Mohammad Mogahed ,
Relator term
700 0# - ADDED ENTRY--PERSONAL NAME
Personal name Hanaa Mostafa Elkaraksy ,
Relator term
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://172.23.153.220/th.pdf">http://172.23.153.220/th.pdf</a>
905 ## - LOCAL DATA ELEMENT E, LDE (RLIN)
Cataloger Enas
Reviser Cataloger
905 ## - LOCAL DATA ELEMENT E, LDE (RLIN)
Cataloger Nazla
Reviser Revisor
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Thesis
Holdings
Source of classification or shelving scheme Not for loan Home library Current library Date acquired Full call number Barcode Date last seen Koha item type Copy number
Dewey Decimal Classification   المكتبة المركزبة الجديدة - جامعة القاهرة قاعة الرسائل الجامعية - الدور الاول 11.02.2024 Cai01.11.28.M.Sc.2015.Sa.S 01010110067381000 22.09.2023 Thesis  
Dewey Decimal Classification   المكتبة المركزبة الجديدة - جامعة القاهرة مخـــزن الرســائل الجـــامعية - البدروم 11.02.2024 Cai01.11.28.M.Sc.2015.Sa.S 01020110067381000 22.09.2023 CD - Rom 67381.CD
Cairo University Libraries Portal Implemented & Customized by: Eng. M. Mohamady Contacts: new-lib@cl.cu.edu.eg | cnul@cl.cu.edu.eg
CUCL logo CNUL logo
© All rights reserved — Cairo University Libraries
CUCL logo
Implemented & Customized by: Eng. M. Mohamady Contact: new-lib@cl.cu.edu.eg © All rights reserved — New Central Library
CNUL logo
Implemented & Customized by: Eng. M. Mohamady Contact: cnul@cl.cu.edu.eg © All rights reserved — Cairo National University Library